British pharma trade body suspends Novo Nordisk for 2 years over serious breaches
London: British pharma trade body, the Association of the British Pharmaceutical Industry (ABPI), has said it has suspended Danish drugmaker Novo Nordisk for two years due to "serious breaches."ABPI's statement linked to a website of a self-regulatory body run by the association that pointed to complaints about Novo Nordisk-sponsored courses on weight management offered on LinkedIn.Read...
Login or Register to read the full article
London: British pharma trade body, the Association of the British Pharmaceutical Industry (ABPI), has said it has suspended Danish drugmaker Novo Nordisk for two years due to "serious breaches."
ABPI's statement linked to a website of a self-regulatory body run by the association that pointed to complaints about Novo Nordisk-sponsored courses on weight management offered on LinkedIn.
Novo is the market leader in a rapidly growing area, the use of medicines - as opposed to dieting or exercising alone - to lose weight.
"While we are disappointed with this outcome, we accept the decision. We will remain committed to following the ABPI Code of Practice and maintaining the highest possible ethical standards required by the pharmaceutical industry," a company spokesperson said.
Read also: Novo Nordisk to cut US list prices for several insulin products by up to 75 percent next year
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd